ABSTRACT
Background The Omicron variant of SARS-CoV-2 is now overtaking the Delta variant in many countries. Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron may indicate that the higher rate of transmission is due to evasion from vaccine-induced immunity. However, there is little information about activation of recall responses to Omicron in vaccinated individuals.
Methods We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively.
Findings Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the SARS-CoV-2 spike and nucleocapsid proteins and spike peptide-induced interferon gamma in whole blood. Both the Omicron and the Delta infected patients had a mild and transient increase in inflammatory parameters.
Interpretation The results suggest that vaccine-induced immunological memory yields similar coverage for the Omicron and Delta variants.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study received the following funding: Oslo University Hospital (JCH, FM), Research Council of Norway (grant no 312780 to JCH, SD; 324274 to AS), The Coalition for Epidemic Preparedness Innovations (FL-J), South-Eastern Norway Regional Health Authority (2019067 and 2021071 to BH; 2021047 and 33612 to AS; 2021087 to GG; 10357 to FL-J, JTA; 2017092 to JAD), EU Horizon 2020 (848099 to BH), The European Virus Archive GLOBAL (EVA-GLOBAL) project that has received funding from the European UnioWs Horizon 2020 research and innovation programme under grant agreement no $71029 (MK), and a philantropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner (JCH). The funders had no role in study design, data collection, or decision to publish this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Regional Committee for Medical and Health Research Ethics in South-Eastern Norway (reference numbers 124170 and 106624).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
